Loading...
•
Sep 30, 2023
Lineage Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023.
Key Takeaways
Lineage Cell Therapeutics reported a net loss of $7.1 million, or $0.04 per share, for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $41.3 million as of September 30, 2023, expected to support operations into Q1 2025. Total revenues for the quarter were $1.2 million.
Lineage team continued to advance clinical and preclinical pipeline.
Continued to support Phase 2a clinical study of OpRegen in patients with geographic atrophy secondary to AMD with Roche and Genentech.
Working on IND amendment submission for OPC1 to initiate DOSED clinical study in spinal cord injury patients.
Initiated development activities under partnership with Eterna Therapeutics.
Forward Guidance
Cash, cash equivalents, and marketable securities totaled $41.3 million as of September 30, 2023, which is expected to support planned operations into Q1 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...